A federal jury in California has ordered Gilead Sciences (Nasdaq: GILD) to pay $200 million in damages to Merck & Co (NYSE: MRK) and its partner Ionis Pharmaceuticals (Nasdaq: IONS) for patent infringement.
It follows a court decision on Tuesday (March 22) to uphold the validity of two patents held by Merck and Ionis for hepatitis C drug sofosbuvir.
Spokeswoman for Gilead, Michele Rest, confirmed the company would appeal the decision.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze